Margolin A, Kosten T R, Avants S K, Wilkins J, Ling W, Beckson M, Arndt I O, Cornish J, Ascher J A, Li S H
Yale University School of Medicine, Department of Psychiatry, New Haven, CT 06519, USA.
Drug Alcohol Depend. 1995 Dec;40(2):125-31. doi: 10.1016/0376-8716(95)01198-6.
We conducted a multi-site, placebo-controlled, randomized double-blind clinical trial comparing bupropion HCL (300 mg/day) to placebo for the treatment of cocaine dependence in methadone-maintained subjects. A total of 149 subjects at three sites participated in a 12-week study. Outcome measures included cocaine use, level of depression, and psychosocial functioning. Results showed no significant differences between placebo and bupropion. Exploratory analyses suggested a medication effect for the subset of subjects depressed at study entry. The need to target subgroups of cocaine abusers in future pharmacotherapy trials and the possible role of treatment readiness are discussed.
我们开展了一项多中心、安慰剂对照、随机双盲临床试验，比较盐酸安非他酮（300毫克/天）与安慰剂治疗美沙酮维持治疗患者可卡因依赖的疗效。三个研究点共有149名受试者参与了一项为期12周的研究。疗效指标包括可卡因使用情况、抑郁程度和社会心理功能。结果显示，安慰剂组和安非他酮组之间无显著差异。探索性分析表明，对于入组时抑郁的受试者亚组存在药物效应。文中讨论了未来药物治疗试验中针对可卡因滥用者亚组的必要性以及治疗准备状态的可能作用。
